Niklas Mattsson-Carlgren
131 – 140 of 230
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Comparing the Clinical Utility and Diagnostic Performance of Cerebrospinal Fluid P-Tau181, P-Tau217 and P-Tau231 Assays
- Contribution to journal › Article
-
Mark
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations
- Contribution to journal › Article
-
Mark
Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease
- Contribution to journal › Article
-
Mark
Association between Apolipoprotein e ϵ2 vs ϵ4, Age, and β-Amyloid in Adults without Cognitive Impairment
- Contribution to journal › Article
-
Mark
The effects of tau, amyloid and white matter lesions on mobility, dual tasking and balance in older people
(2021) In Journals of Gerontology. Series A: Biological Sciences & Medical Sciences 76(4). p.683-691
- Contribution to journal › Article
-
Mark
Associations of Plasma Phospho-Tau217 Levels with Tau Positron Emission Tomography in Early Alzheimer Disease
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
- Contribution to journal › Article
-
Mark
Early stages of tau pathology and its associations with functional connectivity, atrophy and memory
- Contribution to journal › Article
-
Mark
Can reduced attention or visuoexecutive functioning predict perceived walking difficulties in people with Parkinson’s disease (PD)?
- Contribution to journal › Published meeting abstract
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
- Contribution to journal › Scientific review
